Asset Details
Do you wish to reserve the book?
Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
Do you wish to request the book?
Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
2024
Overview
The relative superiority of atezolizumab-bevacizumab versus pembrolizumab-lenvatinib in treatment of unresectable hepatocellular carcinoma (HCC) remains uncertain. This study aims to compare the efficacy of atezolizumab-bevacizumab and pembrolizumab-lenvatinib in first-line treatments for unresectable HCC.
A total of 72 patients receiving pembrolizumab-lenvatinib (PL group) and 92 patients receiving atezolizumab-bevacizumab (AB group) between January 2019 and June 2023 were included in this study. By employing propensity score matching (PSM), we compared the overall survival (OS) and progression-free survival (PFS) between the two groups.
After PSM, the 1-, 2-, and 3-year OS rates were 70.4%, 54.5%, and 40.0% in the PL group, and 88.4%, 44.2%, and 44.2% in the AB group, respectively. The 6-, 12-, and 18-month PFS rates were 56.9%, 43.0%, and 32.1% in the PL group, and 74.2%, 40.9%, and 30.7% in the AB group, respectively. No significant differences were observed in both OS (HR, 0.498; 95% CI, 0.217-1.143;
= 0.1) and PFS (HR, 0.913; 95% CI, 0.512-0.1.629;
= 0.758) between the two groups. Through subgroup analysis, we developed a Cirrhosis-Portal vein invasion-ALBI (CPA) score and identified that the AB group exhibited significantly longer OS than the PL group in the CPA high population (HR, 0.219; 95% CI, 0.075-0.637;
= 0.005). The treatment-related adverse events between the PL group and the AB group were comparable.
This study suggests that the efficacy of pembrolizumab-lenvatinib and atezolizumab-bevacizumab is comparable in first-line treatment of unresectable HCC, the atezolizumab-bevacizumab combination may confer additional benefits for patients with high CPA scores compared to pembrolizumab-lenvatinib.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Aged
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Bevacizumab - administration & dosage
/ Bevacizumab - adverse effects
/ Bevacizumab - therapeutic use
/ Carcinoma, Hepatocellular - drug therapy
/ Carcinoma, Hepatocellular - mortality
/ Disease
/ Female
/ Humans
/ Liver Neoplasms - drug therapy
/ Male
/ Survival
